Royal Bank of Canada’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-135,000
| Closed | -$145M | – | 7432 |
|
|
2025
Q4 | $145M | Buy |
135,000
+35,000
| +35% | +$33.5M | 0.02% | 518 |
|
|
2025
Q3 | $76.3M | Hold |
100,000
| – | – | 0.01% | 811 |
|
|
2025
Q2 | $78M | Buy |
100,000
+40,000
| +67% | +$31.1M | 0.01% | 733 |
|
|
2025
Q1 | $49.6M | Buy |
60,000
+45,000
| +300% | +$37.4M | 0.01% | 799 |
|
|
2024
Q4 | $11.6M | Sell |
15,000
-35,000
| -70% | -$29M | ﹤0.01% | 1712 |
|
|
2024
Q3 | $44.3M | Buy |
+50,000
| New | +$45M | 0.01% | 875 |
|
|
2022
Q4 | – | Sell |
-37,900
| Closed | -$12.3M | – | 7497 |
|
|
2022
Q3 | $12.3M | Buy |
37,900
+11,800
| +45% | +$3.74M | ﹤0.01% | 1389 |
|
|
2022
Q2 | $8.46M | Sell |
26,100
-13,400
| -34% | -$4.02M | ﹤0.01% | 1676 |
|
|
2022
Q1 | $11.3M | Buy |
+39,500
| New | +$10.2M | ﹤0.01% | 1634 |
|
|
2021
Q4 | – | Sell |
-15,400
| Closed | -$3.56M | – | 7798 |
|
|
2021
Q3 | $3.56M | Buy |
+15,400
| New | +$3.8M | ﹤0.01% | 2589 |
|
|
2019
Q3 | – | Sell |
-300
| Closed | -$33K | – | 6922 |
|
|
2019
Q2 | $33K | Sell |
300
-14,400
| -98% | -$1.7M | ﹤0.01% | 5474 |
|
|
2019
Q1 | $1.91M | Sell |
14,700
-7,700
| -34% | -$936K | ﹤0.01% | 2720 |
|
|
2018
Q4 | $2.59M | Sell |
22,400
-81,800
| -79% | -$9.14M | ﹤0.01% | 2462 |
|
|
2018
Q3 | $11.2M | Buy |
104,200
+33,000
| +46% | +$3.3M | ﹤0.01% | 1546 |
|
|
2018
Q2 | $6.08M | Sell |
71,200
-3,400
| -5% | -$279K | ﹤0.01% | 1878 |
|
|
2018
Q1 | $5.77M | Sell |
74,600
-16,400
| -18% | -$1.32M | ﹤0.01% | 1900 |
|
|
2017
Q4 | $7.69M | Sell |
91,000
-87,000
| -49% | -$7.4M | ﹤0.01% | 1780 |
|
|
2017
Q3 | $15.2M | Buy |
178,000
+29,000
| +19% | +$2.38M | 0.01% | 1263 |
|
|
2017
Q2 | $12.3M | Buy |
149,000
+36,600
| +33% | +$2.99M | 0.01% | 1375 |
|
|
2017
Q1 | $9.45M | Sell |
112,400
-458,900
| -80% | -$36.8M | 0.01% | 1520 |
|
|
2016
Q4 | $42M | Buy |
571,300
+229,500
| +67% | +$17.1M | 0.02% | 603 |
|
|
2016
Q3 | $27.4M | Buy |
341,800
+53,400
| +19% | +$4.27M | 0.02% | 809 |
|
|
2016
Q2 | $22.7M | Sell |
288,400
-1,108,200
| -79% | -$83.4M | 0.01% | 881 |
|
|
2016
Q1 | $101M | Buy |
1,396,600
+1,373,200
| +5,868% | +$104M | 0.06% | 243 |
|
|
2015
Q4 | $1.97M | Sell |
23,400
-73,700
| -76% | -$6.12M | ﹤0.01% | 2566 |
|
|
2015
Q3 | $8.13M | Buy |
97,100
+73,500
| +311% | +$6.21M | 0.01% | 1277 |
|
|
2015
Q2 | $1.97M | Buy |
+23,600
| New | +$1.8M | ﹤0.01% | 2327 |
|
|
2014
Q1 | – | Sell |
-13,700
| Closed | -$699K | – | 6028 |
|
|
2013
Q4 | $699K | Sell |
13,700
-6,400
| -32% | -$320K | ﹤0.01% | 3147 |
|
|
2013
Q3 | $1.01M | Buy |
20,100
+6,400
| +47% | +$335K | ﹤0.01% | 2755 |
|
|
2013
Q2 | $673K | Buy |
+13,700
| New | +$745K | ﹤0.01% | 2881 |
|
Other funds holding LLY
VCM
VPM
Royal Bank of Canada's LLY Position: Q1 2026 in Review
Royal Bank of Canada reduced its Eli Lilly (LLY) stake by 2.5% in Q1 2026, selling an estimated $109M and leaving 4,262,531 shares worth $3.92B. The position accounts for 0.69% of the portfolio, ranked #26.
Royal Bank of Canada first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.7B in Q4 2025. 4,366 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Royal Bank of Canada held 4,262,531 shares of Eli Lilly worth $3.92B as of Q1 2026.
- Royal Bank of Canada sold 107,202 Eli Lilly shares in Q1 2026, an estimated $109M.
- Eli Lilly made up 0.69% of Royal Bank of Canada's portfolio in Q1 2026, its #26 holding.
- Royal Bank of Canada first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
- Royal Bank of Canada's Eli Lilly position peaked at $4.7B in Q4 2025.
- 4,366 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.